Medeikon announces collaboration with American Cardiovascular Research Institute.

EWING, N.J. -- Medeikon Announces Collaboration with ACRI to Leverage and Combine Best-in-Class Technology to Identify and Treat Cardiac Disease

Medeikon Corporation provides medical devices that enable physicians to accurately diagnose and treat cardiovascular disease. Medeikon's initial emphasis is on rupture-prone plaque, the leading cause of sudden cardiac death. Medeikon's XploraPD(TM) system helps physician's distinguish these rupture-prone lesions from other types of coronary artery tissue using optical technologies. This allows physicians to make early and accurate diagnosis and then treat the condition with tools consistent with current cardiac catheterization techniques and equipment.

According to Cristian Toma, PhD, Research and Development, "Interventional Cardiologists require solutions that leverage and combine best-in-class technology to identify and treat cardiac disease. Our company is organized around developing a platform capability with optical technologies for the detection and treatment of diseased cardiovascular tissues. Our business model is to develop key strategic relationships with medical research and hospitals for pre-clinical and clinical experiments. Our relationship with ACRI is essential in building a library of reference signals, which plays a central role in our algorithm development process."

Today's healthcare market demands solutions designed to improve quality of care. Medeikon is delivering an advanced portfolio of cardiology systems that provide real-time data within the constraints of a typical catheter lab procedure. Medeikon is meeting those healthcare demands through collaborating with key medical advisors. We are excited to collaborate with ACRI and Nicholas A.F. Chronos, MD, the Chief Medical and Scientific Officer for pre-clinical trials and histology. Dr Chronos stated, "ACRI is delighted to work on this innovative technology from Medeikon which clearly has the potential to change our understanding of coronary pathophysiology. Through the application of light through a 0.14 F guide wire, we believe that the Medeikon technology will enable practicing interventional cardiologists to better understand, diagnose and treat conditions in the coronary arteries including restenosis, cardiac arrhythmia and vulnerable plaque. It is clear that the years of expertise in optics brought by the technical team at Medeikon will dramatically enhance the development of usable imaging technologies and provide the cardiologists with an optimal tool for use in every interventional cardiology setting."

ACRI and Medeikon are working together to bring this technology, which is an example of true translation, from preclinical study to clinical trial and education.

Medeikon is currently in the development stage. Medeikon is a privately held company. Medeikon is currently engaged in a private placement for Round B financing for $20 million.

ACRI integrates research, technology, data and education into a continuum of enhanced care for the cardiovascular patient. ACRI conducts preclinical and clinical studies funded through grants from the National Institutes of Health, the medical device and pharmaceutical industries, and philanthropic organizations. ACRI maintains an informatics team to develop information systems that support the clinical management of patients and the efficiency and performance of clinical trials.